Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140026/S032

ENROUTE Transcarotid Stent System

BOSTON SCIENTIFIC CORPORATION · Decision date Oct 23, 2025

FDA DECISIONP140026/S032

What did the FDA decide?

FDA records P140026/S032 as a supplement to PMA P140026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 23, 2025.

FDA approval order statement

to transfer post-laser manufacturing processes of the stent component from Confluent in Fremont, California, to Confluent in Costa Rica
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 23, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140026/S032
Regulatory pathway
PMA supplement
Product code
NIM
Decision code
OK30
Decision date
Oct 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, carotid.

Product code
NIM
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140026/S032 received

    Application receipt date recorded by FDA.

  2. P140026/S032 · FDA decision

    30-Day Notice

  3. P140026/S033 · Related supplement

    ENROUTE Transcarotid Stent System

Timeline entries are records held by MedtechLedger for P140026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140026

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementJan 8, 2026FDA

Explore the linked device profile

Other records with product code NIM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
300 Boston Scientific Way, Marborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records